ATE291614T1 - Diagnose und behandlung von zellproliferativen erkrankungen mit beteiligung von klonalen makrophagen - Google Patents
Diagnose und behandlung von zellproliferativen erkrankungen mit beteiligung von klonalen makrophagenInfo
- Publication number
- ATE291614T1 ATE291614T1 AT95930787T AT95930787T ATE291614T1 AT E291614 T1 ATE291614 T1 AT E291614T1 AT 95930787 T AT95930787 T AT 95930787T AT 95930787 T AT95930787 T AT 95930787T AT E291614 T1 ATE291614 T1 AT E291614T1
- Authority
- AT
- Austria
- Prior art keywords
- macrophages
- clonal
- cancerous
- cell proliferative
- diagnosis
- Prior art date
Links
- 210000002540 macrophage Anatomy 0.000 title abstract 6
- 210000004027 cell Anatomy 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000002062 proliferating effect Effects 0.000 title abstract 3
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000035755 proliferation Effects 0.000 abstract 2
- 230000010354 integration Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5055—Cells of the immune system involving macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- AIDS & HIV (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/286,745 US5580715A (en) | 1994-08-05 | 1994-08-05 | Diagnosis of cancer having clonal macrophage involvement |
| US08/473,040 US5639600A (en) | 1994-08-05 | 1995-06-06 | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
| PCT/US1995/009715 WO1996004019A1 (en) | 1994-08-05 | 1995-08-01 | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE291614T1 true ATE291614T1 (de) | 2005-04-15 |
Family
ID=26964048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95930787T ATE291614T1 (de) | 1994-08-05 | 1995-08-01 | Diagnose und behandlung von zellproliferativen erkrankungen mit beteiligung von klonalen makrophagen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5639600A (de) |
| EP (1) | EP0772456B1 (de) |
| JP (1) | JPH10503656A (de) |
| AT (1) | ATE291614T1 (de) |
| AU (1) | AU700490B2 (de) |
| CA (1) | CA2196776A1 (de) |
| DE (1) | DE69534100T2 (de) |
| WO (1) | WO1996004019A1 (de) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6140098A (en) * | 1996-08-30 | 2000-10-31 | Schering Corporation | Nucleic acids encoding mammalian proteinases; related reagents |
| EP0960210A4 (de) * | 1996-10-04 | 2004-06-09 | Chronix Biomedical | Diagnostische nukleinsäure-detektion |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| US8198334B2 (en) * | 1997-10-27 | 2012-06-12 | Pathologica Llc | Methods for modulating macrophage proliferation in ocular disease using polyamine analogs |
| WO2001074388A1 (en) * | 2000-03-31 | 2001-10-11 | Idec Pharmaceuticals Corporation | Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma |
| JP2005502618A (ja) * | 2001-06-04 | 2005-01-27 | ザ・ジェネラル・ホスピタル・コーポレイション | 光力学的化合物を用いて脆弱なプラークを検出および治療する方法 |
| US20030064965A1 (en) * | 2001-10-02 | 2003-04-03 | Jacob Richter | Method of delivering drugs to a tissue using drug-coated medical devices |
| US20030186246A1 (en) * | 2002-03-28 | 2003-10-02 | Willey James C. | Multiplex standardized reverse transcriptase-polymerase chain reacton method for assessment of gene expression in small biological samples |
| NO326130B1 (no) * | 2002-10-08 | 2008-10-06 | Enok Tjotta | Fremgangsmate for seleksjon og testing av forbindelser som inhiberer eller stimulerer klonal cellevekst |
| US7917306B2 (en) * | 2005-03-30 | 2011-03-29 | Yeda Research And Developement Co. Ltd. | Methods and systems for generating cell lineage tree of multiple cell samples |
| CN101300004B (zh) * | 2005-09-23 | 2013-08-21 | 帕瑟洛吉卡有限公司 | 使用多胺类似物治疗病毒感染的方法 |
| WO2007047408A2 (en) * | 2005-10-12 | 2007-04-26 | Pathologica, Llc. | Promac signature application |
| CA2659956C (en) | 2006-08-04 | 2016-01-05 | Lewis C. Cantley | Inhibitors of pyruvate kinase and methods of treating disease |
| DK2121586T3 (en) * | 2007-03-09 | 2017-06-19 | Pathologica Llc | MGBG FOR THE REGULATION OF OSTEOPONTIN AND THE TREATMENT OF MULTIPLE SCLEROSIS |
| NZ590667A (en) * | 2008-07-02 | 2013-01-25 | Emergent Product Dev Seattle | Tgf-b antagonist multi-target binding proteins |
| JP6112449B2 (ja) | 2009-07-16 | 2017-04-12 | パソロジカ エルエルシー | Ｍｇｂｇを含む経口送達用の医薬品および疾患を処置する方法 |
| US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
| WO2011056561A1 (en) | 2009-10-27 | 2011-05-12 | Beth Israel Deaconess Medical Center | Methods and compositions for the generation and use of conformation-specific antibodies |
| US20130109672A1 (en) | 2010-04-29 | 2013-05-02 | The United States Of America,As Represented By The Secretary, Department Of Health And Human Service | Activators of human pyruvate kinase |
| NO2665471T3 (de) | 2011-01-19 | 2018-05-26 | ||
| WO2012112245A1 (en) | 2011-02-14 | 2012-08-23 | Beth Israel Deaconess Medical Center, Inc. | Modulation of phosphatidylinositol-5-phosphate-4-kinase activity |
| US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
| CN109432073A (zh) | 2013-01-08 | 2019-03-08 | 帕萨罗杰卡有限公司 | Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途 |
| US10683308B2 (en) | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| AU2016342027B2 (en) | 2015-10-23 | 2021-05-13 | Navitor Pharmaceuticals, Inc. | Modulators of Sestrin-GATOR2 interaction and uses thereof |
| EP3389664A4 (de) | 2015-12-14 | 2020-01-08 | Raze Therapeutics Inc. | Koffeininhibitoren von mthfd2 und verwendungen dafür |
| EP4234552A3 (de) | 2016-03-09 | 2023-10-18 | Raze Therapeutics, Inc. | 3-phosphoglycerat-dehydrogenase-inhibitoren und verwendungen davon |
| DK3426243T3 (da) | 2016-03-09 | 2021-07-19 | Raze Therapeutics Inc | 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf |
| WO2018089499A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF |
| US11091451B2 (en) | 2016-12-05 | 2021-08-17 | Raze Therapeutics, Inc. | SHMT inhibitors and uses thereof |
| WO2018191146A1 (en) | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
| PL3615019T3 (pl) | 2017-04-26 | 2026-01-19 | Navitor Pharmaceuticals, Inc. | Modulator interakcji sestryna-gator2 do zastosowania w leczeniu depresji opornej na leczenie |
| WO2019109046A1 (en) | 2017-11-30 | 2019-06-06 | Arrakis Therapeutics, Inc. | Nucleic acid-binding photoprobes and uses thereof |
| US20210011006A1 (en) * | 2018-02-27 | 2021-01-14 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered immune cells as diagnostic probes of disease |
| WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| EP3870158A4 (de) | 2018-10-24 | 2022-08-10 | Navitor Pharmaceuticals, Inc. | Polymorphe verbindungen und verwendungen davon |
| US11723890B2 (en) | 2019-11-01 | 2023-08-15 | Navitor Pharmaceuticals, Inc. | Methods of treatment using an mTORC1 modulator |
| AU2020397938A1 (en) | 2019-12-05 | 2022-06-23 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4699877A (en) * | 1982-11-04 | 1987-10-13 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
| US4681840A (en) * | 1984-01-18 | 1987-07-21 | The United States Of America As Represented By The Secretary Of Commerce | Deoxyribonucleic acid molecules useful as probes for detecting oncogenes incorporated into chromosomal DNA |
| US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5177192A (en) * | 1987-04-02 | 1993-01-05 | Centocor, Incorporated | Method for labeling antibodies with a metal ion |
| US4869903A (en) * | 1987-05-29 | 1989-09-26 | Genelabs Incorporated | Method of selectively inhibiting HIV |
| US4795739A (en) * | 1987-05-29 | 1989-01-03 | Gene Labs, Inc. | Method of inhibiting HIV |
| US5180816A (en) * | 1988-08-24 | 1993-01-19 | Centocor | One vial method for labeling protein/linker conjugates with technetium-99M |
| US5225326A (en) * | 1988-08-31 | 1993-07-06 | Research Development Foundation | One step in situ hybridization assay |
| DE69230136T2 (de) * | 1991-01-14 | 2000-05-25 | New York University, New York | Cytokin-induziertes protein, tsg-6, seine dna und verwendung |
| US5445940A (en) * | 1991-08-28 | 1995-08-29 | Brigham & Women's Hospital | Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease |
-
1995
- 1995-06-06 US US08/473,040 patent/US5639600A/en not_active Expired - Lifetime
- 1995-08-01 AT AT95930787T patent/ATE291614T1/de not_active IP Right Cessation
- 1995-08-01 WO PCT/US1995/009715 patent/WO1996004019A1/en not_active Ceased
- 1995-08-01 JP JP8506701A patent/JPH10503656A/ja active Pending
- 1995-08-01 AU AU34037/95A patent/AU700490B2/en not_active Ceased
- 1995-08-01 EP EP95930787A patent/EP0772456B1/de not_active Expired - Lifetime
- 1995-08-01 DE DE69534100T patent/DE69534100T2/de not_active Expired - Fee Related
- 1995-08-01 CA CA002196776A patent/CA2196776A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU3403795A (en) | 1996-03-04 |
| US5639600A (en) | 1997-06-17 |
| WO1996004019A1 (en) | 1996-02-15 |
| CA2196776A1 (en) | 1996-02-15 |
| EP0772456A1 (de) | 1997-05-14 |
| AU700490B2 (en) | 1999-01-07 |
| EP0772456B1 (de) | 2005-03-23 |
| JPH10503656A (ja) | 1998-04-07 |
| DE69534100T2 (de) | 2006-03-23 |
| EP0772456A4 (de) | 1999-06-30 |
| DE69534100D1 (de) | 2005-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE291614T1 (de) | Diagnose und behandlung von zellproliferativen erkrankungen mit beteiligung von klonalen makrophagen | |
| CY1122817T1 (el) | Νεα αντι-il 13 αντισωματα και χρησεις αυτων | |
| BR9912053A (pt) | Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios | |
| TNSN05300A1 (en) | Treatment with anti-vegf antibodies | |
| ES2148171T3 (es) | Gen mutado en cancer colorrectal de humanos. | |
| ES2158115T3 (es) | Derivados de histidina y homohistidina como inhibidores de la farnesiltransferasa de proteinas. | |
| NO20002979D0 (no) | Undersøkelse av human papillomavirus-relatert sykdom | |
| DE69933989D1 (de) | Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten | |
| CY1110256T1 (el) | Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου | |
| NO20014560L (no) | Quinasoliner og terapautisk anvendelse derav | |
| WO2004113571A3 (en) | Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis | |
| ATE435281T1 (de) | Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung | |
| ATE380548T1 (de) | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie | |
| DE59611341D1 (de) | Verwendung von saccharid-konjugaten | |
| CY1115407T1 (el) | Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων | |
| ATE350030T1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
| BR0010702A (pt) | Novas quinonas como terapias de doenças | |
| DE69911380D1 (de) | Verwendung von isatin- und oxindolderivaten zur herstellung von arzeneimittel für die behandlung von mykobakteriellen erkrankungen | |
| CY1111522T1 (el) | 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο | |
| DE60005952D1 (de) | Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| AU2002251754A1 (en) | Therapeutic modulation of the tumor inflammatory response | |
| HUP0300007A2 (en) | Antibody with specificity for colon cancer | |
| DE60139150D1 (de) | Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs | |
| AU2003229876A1 (en) | Tumour associated antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |